DAYVIGO 5MG TABLET

Introduction:

Dayvigo 5mg Tablet contains Lemborexant as the active constituent. It is used in the treatment of insomnia in adult patients. Insomnia has been characterized as a sleep disorder that makes it hard for a person to fall asleep. Insomnia is developed as a consequence of poor lifestyle, improper sleep schedule, and psychological distress such as stress, anxiety, and depression. It is recommended to consume this medicine only once per night, right before going to bed. It is best to plan the sleep schedule and follow a minimum of 7-8 of sleep while taking this medicine to prevent the risk of daytime sleepiness.

It is intended for oral use only. This medicine is not advised for people suffering from a chronic sleep disorder. Do not discontinue this medicine without seeking proper advice from your doctor. Avoid consuming alcohol while using Dayvigo 5 mg Tablet. It is better to avoid driving immediately the next morning as this medicine can reduce your driving potential. Inform your physician if you have had a history of depression or addiction to alcohol or habit-forming substances. It is recommended to maintain a proper interval between your meal and intake of this medicine as it can cause a delay in its onset of action.

Uses of Dayvigo 5mg Tablet:

Dayvigo 5mg Tablet has been approved for treating the following conditions

• Insomnia – difficulty in sleeping.

How Dayvigo 5mg Tablet works:

Dayvigo 5mg Tablet works by inhibiting the orexin signals in the brain. Orexin is a chemical produced by the hypothalamus of the brain that promotes wakefulness and is also responsible for the sleep-wake cycle. Therefore, Dayvigo 5mg Tablet produces its action by acting as a competitive blocker by preventing the binding of orexin-A and B proteins to the OX1 AND OX2 receptors. Thereby this medicine helps to suppress the wakefulness.

Interactions with other drugs:

Inform your doctor about any medications you are taking or have taken before the treatment.

More information:

• Keep Dayvigo 5mg Tablet out of sight and reach of children.
• Keep this medicine in a safe place to prevent misuse.
• Store it at room temperature not exceeding 25°C.

References:

1. Rosenberg et al; Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies; Neuropsychiatric Disease and Treatment 2021:17 2549–2566; Published on August 2021; Accessed on 15/07/2022; https://www.dovepress.com/getfile.php?fileID=72977
2. Eisai Inc, US Food and Drug Administration, [ Issued on  March 2022], [Accessed on 16th June 2022], https://www.dayvigo.com/-/media/Files/DAYVIGO/PDF/prescribing-information.pdf?hash=29123669-6b3b-4728-ab27-b2e49ef34788
3. Yardley J, Kärppä M, Inoue Y et al; Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Medicine; Published on April 2021; Accessed on 15/07/2022; https://www.sciencedirect.com/science/article/pii/S1389945721000654
4. Eisai Inc, Medication Guide, Dayvigo, [ Issued on March 2022], [ Accessed on 16th June 2022], https://www.dayvigo.com/-/media/Files/DAYVIGO/PDF/

Disclaimer: City Medicine Corner primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on City Medicine Corner. Our mission is to support, not replace, the doctor-patient relationship.